# PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

“PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer” (2016), by Andreas Daniel Hartkopf et al. Medicine research paper. Original abstract below, unchanged. No free PDF was found.

- Authors: Andreas Daniel Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, Christina Barbara Walter, Bernhard Krämer, Eva‐Maria Grischke, Sara Yvonne Brucker
- Published: January 1, 2016
- Field: Medicine
- DOI: https://doi.org/10.1159/000453569
- Source: https://doi.org/10.1159/000453569

## Abstract

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.

Canonical page: https://nerdi.pages.dev/paper/W2560367415
Read three real papers a day in Nerdi (iPhone): https://apps.apple.com/app/apple-store/id6813826387?pt=128757794&ct=web-paper&mt=8